Réanimation Médicale et Toxicologique, INSERM UMRS1144, AP-HP, Hôpital Lariboisière, Université de Paris, Paris, France.
Service d'Anatomie et Cytologie Pathologiques, INSERM UMR 1141, AP-HP, Hôpital Lariboisière, Université de Paris, Paris, France.
Clin Respir J. 2022 Apr;16(4):329-334. doi: 10.1111/crj.13481. Epub 2022 Mar 11.
Coronavirus disease-2019 (COVID-19) may lead to acute respiratory distress syndrome requiring extracorporeal membrane oxygenation (ECMO). Patterns of inflammatory bronchoalveolar cells in COVID-19 patients treated with ECMO are not well described.
We aimed to describe inflammatory cell subpopulations in blood and bronchoalveolar lavages (BALs) obtained in critically ill COVID-19 patients shortly after ECMO implementation.
BAL was performed in the middle lobe in 12 consecutive ECMO-treated COVID-19 patients. Trained cytologists analyzed peripheral blood and BAL cells using flow cytometry and routine staining, respectively. Data were interpreted in relation to dexamethasone administration and weaning from ECMO and ventilator.
High neutrophil proportions (66% to 88% of total cells) were observed in the absence of bacterial superinfection and more frequently in dexamethasone-free patients (83% [82-85] vs. 29% [8-68], P = 0.006), suggesting that viral infection could be responsible of predominantly neutrophilic lung inflammation. Successful weaning from ECMO/ventilator could not be predicted by the peripheral white blood and BAL cell pattern.
High neutrophil proportions can be observed in critically ill COVID-19 patients despite the lack of microbiological evidence on BAL of bacterial superinfection. Dexamethasone was associated with lower neutrophil proportions in BAL. Our study was probably underpowered to provide BAL cell pattern helpful to predict weaning from ECMO/ventilator.
新型冠状病毒病 2019(COVID-19)可能导致需要体外膜肺氧合(ECMO)的急性呼吸窘迫综合征。接受 ECMO 治疗的 COVID-19 患者的炎症性支气管肺泡细胞模式尚未得到很好的描述。
我们旨在描述 ECMO 实施后不久,重症 COVID-19 患者血液和支气管肺泡灌洗液(BAL)中的炎症细胞亚群。
对 12 例连续接受 ECMO 治疗的 COVID-19 患者进行了中叶 BAL。训练有素的细胞学家分别使用流式细胞术和常规染色分析外周血和 BAL 细胞。根据地塞米松给药和 ECMO 及呼吸机脱机情况对数据进行解释。
在没有细菌合并感染的情况下,观察到高比例的中性粒细胞(占总细胞的 66%至 88%),并且在未使用地塞米松的患者中更为常见(83%[82-85]比 29%[8-68],P=0.006),提示病毒感染可能导致以中性粒细胞为主的肺部炎症。外周白细胞和 BAL 细胞模式并不能预测 ECMO/呼吸机脱机是否成功。
尽管 BAL 无细菌合并感染的微生物学证据,但在重症 COVID-19 患者中仍可观察到高比例的中性粒细胞。地塞米松与 BAL 中的中性粒细胞比例降低相关。我们的研究可能没有足够的能力提供有助于预测 ECMO/呼吸机脱机的 BAL 细胞模式。